Skip to content
2000
Volume 7, Issue 2
  • ISSN: 1568-0096
  • E-ISSN: 1873-5576

Abstract

Oncolytic viruses can selectively replicate in and lead to tumor cell lysis with minimal infection/replication potential in adjoining non-neoplastic tissue. Because of paramount safety concerns, first-generation oncolytic viruses were designed to be significantly attenuated in their lytic potential. Results from recent clinical trials have revealed the safety of this approach, but have underscored the urgency for design and testing of more tumor-selective and -potent viruses to realize the full therapeutic potential of this revolutionary treatment modality. With the discovery of various molecular/genetic changes associated with neoplasia, tumor-specific transcriptional targeting of viral virulence is being tapped to generate tumor- and tissue-specific variants. This review will focus on the various strategies exploited to generate viruses whose virulence is governed by tumorspecific transcriptional events.

Loading

Article metrics loading...

/content/journals/ccdt/10.2174/156800907780058880
2007-03-01
2025-06-12
Loading full text...

Full text loading...

/content/journals/ccdt/10.2174/156800907780058880
Loading

  • Article Type:
    Research Article
Keyword(s): adenovirus; cancer; HSV-1; Oncolytic viruses; promoter; transcriptional regulation
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test